Science Corp., led by Max Hodak, is advancing its plans to insert its pioneering sensor into a human brain, with human trials expected to unfold in the years ahead. This marks a significant step for the company as it ventures into in-vivo testing of its technology.
The hybrid sensor represents a novel approach to interfacing with neural tissue, combining both hardware and biological components. The company anticipates that data gathered from these trials will inform future iterations of the sensor and guide further research.
Max Hodak has not yet released a detailed timeline for the commencement of the trials, but has confirmed that preparations are underway. The outcomes of these initial trials will be crucial in determining the long-term viability and potential applications of the sensor technology.